## Prevalence and associated factors of depression in patients with psoriasis at psoriasis clinic in a university hospital in Thailand



Mahidol University Faculty of Medicine Siriraj Hospital

 Kamonporn Wannarit\*, Chanisada Wongpraparut\*\*, Leena Chularojanamontri\*\* Narumol Silpa-archa\*\*, Nutchanart Tayeh\*, Punyisa Prachgosin\*, Woraphat Ratta-apha\*
\* Department of Psychiatry, Faculty of medicine, Siriraj Hospital, Mahidol University.
\*\* Department of Dermatology, Faculty of medicine, Siriraj Hospital, Mahidol University.

#### Background

Patients with psoriasis not only suffer from several physically burdensome symptoms, but also from depression and stress. In addition, psoriasis may affect their quality of life as well.

#### **Objectives**

To investigate the prevalence and associated factors of depression in patients with psoriasis.

#### **Materials and methods**

Patients with psoriasis were invited to complete the Thai versions of Patient Health Questionnaire (PHQ-9), Perceived Stress Scale-10, Alcohol Use Disorders Identification Test, Fagerström Test for Nicotine Dependence, Psoriasis Disability Index (PDI), Psoriasis Area and Severity Index and Simplified Psoriasis Index (SPI). T-test and chisquare test were used to examine associated factors of depression. Pearson's correlation was

### **Results**

After 150 patients were assessed, 21.33% of them had depression. Higher scores of stress level, subjective psychosocial impact of psoriasis, selfperceived current severity of psoriasis and more impaired quality of life were significantly associated with depression (p < 0.05). Depression severity was positively correlated with the severity of alcohol drinking, perceived stress, quality of life impairment, current severity and psychosocial impact of psoriasis (p < 0.05).

#### Conclusions

Depression is prevalent among patients with psoriasis. Those with high perceived-stress and high psychosocial impact of psoriasis and more severe disease activity should be evaluated for depression as it can hamper their quality of life.

# used to investigate relationship between severity of depression and other mental health problems.

Table 1: Comparison of psoriasis impact on participants who had depression and did not have depression using t-test (n = 150)

Variable	Participants who had depression	Participants who did not have depression (N= 118)	<i>P</i> -value
	(N=32)		
	$Mean \pm SD$	$Mean \pm SD$	
<sup>a</sup> T-PSS-10	$17.94 \pm 4.50$	$15.08\pm5.40$	0.007*
<sup>b</sup> PASI	$11.080\pm9.01$	$8.79\pm8.35$	0.190
<sup>c</sup> proSPI Severity	12.69 ± 7.84	$10.75\pm9.93$	0.150
<sup>c</sup> proSPI Psychosocial	$5.58\pm~3.07$	$3.76\pm2.75$	0.002*
<sup>c</sup> proSPI Intervention	$3.29\pm2.08$	2.91± 2.02	0.363
dsaSPI Severity	$12.24\pm10.89$	$6.80\pm\ 7.35$	0.001*
dsaSPI Psychosocial	5.25 ± 2.35	$3.19\pm\ 2.64$	0.000*
dsaSPI Intervention	$2.84 \pm 2.27$	$2.98\pm2.09$	0.744
Psoriasis Disability Index (PDI)	$12.69 \pm 7.84$	6.07± 5.86	<0.001*

\* *P*-value < 0.05

<sup>a</sup>T-PSS-10: Thai Perceived Stress Scale-10; <sup>b</sup>PASI: Psoriasis Area and Severity Index; <sup>c</sup>proSPI: Simplified Psoriasis Index-health professional assessment; <sup>d</sup>saSPI: Simplified Psoriasis Index-patient self-assessment

Variables	Coefficient of Correlation (r)	<i>P</i> -value
Alcohol Use Disorders Identification Test (AUDIT)	0.227	0.005*
Psoriasis Disability Index (PDI)	0.523	<0.001*
T-PSS-10	0.336	<0.001*
PASI	0.161	0.093
proSPI Severity	0.311	0.050
proSPI Psychosocial	0.032	<0.001*
proSPI Intervention	0.103	0.212
saSPI Severity	0.311	<0.001*
saSPI Psychosocial	0.352	<0.001*
saSPI Intervention	0.112	0.171

\* *P*-value < 0.05

#### References

1. Lamb R, Matcham F, Turner M, Rayner L, Simpson A, Hotopf M et al. Screening for anxiety and depression in people with psoriasis: a cross-sectional study in a tertiary referral setting. Br J Dermatol. 2017;176(4):1028-34.

2. McDonough E, Ayearst R, Eder L, Chandran V, Rosen CF, Thavaneswaran A et al. Depression and anxiety in psoriatic disease: prevalence and associated factors. J Rheumatol. 2014;41(5):887-96.